|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
13876 Achieving a PASI 50 at 2 weeks was associated with better long-term clinical outcomes and low discontinuation: A subgroup analysis of a phase 3 trial of ixekizumab and etanercept in moderate to severe psoriasis |
Vir: |
|
|
|
List of services to meet your request
Contains list of services for current record
|
|
|
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
|